658690-97-2

Upstream product

• 658690-96-1 1,1-dimethylethyl {(1S)-2-(3,4-difluorophenyl)-1-[(2S)-2-oxiranyl]ethyl}carbamate 
• 5071-96-5 3-METHOXYBENZYLAMINE 

Downstream Products

• 658690-98-3 (3S,2R)-3-amino-4-(3,4-difluoro-phenyl)-1-(3-methoxy-benzylamino)-butan-2-ol 

Relevant academic research and scientific papers

NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS

There is provided a series of novel substituted gamma-lactams of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of aβ-peptide. The present invention is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.